BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 25501962)

  • 1. Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients.
    Szopa M; Osmenda G; Wilk G; Matejko B; Skupien J; Zapala B; Młynarski W; Guzik T; Malecki MT
    Eur J Endocrinol; 2015 Mar; 172(3):277-83. PubMed ID: 25501962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N; Hohendorff J; Solecka I; Szopa M; Skupien J; Kiec-Wilk B; Mlynarski W; Malecki MT
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing.
    López-Garrido MP; Herranz-Antolín S; Alija-Merillas MJ; Giralt P; Escribano J
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):342-7. PubMed ID: 23009393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three unreported glucokinase (GCK) missense mutations detected in the screening of thirty-two Brazilian kindreds for GCK and HNF1A-MODY.
    Weinert LS; Silveiro SP; Giuffrida FM; Cunha VT; Bulcão C; Calliari LE; Della Manna T; Kunii IS; Dotto RP; Dias-da-Silva MR; Reis AF
    Diabetes Res Clin Pract; 2014 Nov; 106(2):e44-8. PubMed ID: 25174781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL cholesterol as a diagnostic tool for clinical differentiation of GCK-MODY from HNF1A-MODY and type 1 diabetes in children and young adults.
    Fendler W; Borowiec M; Antosik K; Szadkowska A; Deja G; Jarosz-Chobot P; Mysliwiec M; Wyka K; Pietrzak I; Skupien J; Malecki MT; Mlynarski W
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):321-7. PubMed ID: 21521320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations.
    Ben Khelifa S; Martinez R; Dandana A; Khochtali I; Ferchichi S; Castaño L
    Gene; 2018 Apr; 651():44-48. PubMed ID: 29408271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Retinopathy in Adult Patients with GCK-MODY and HNF1A-MODY.
    Szopa M; Wolkow J; Matejko B; Skupien J; Klupa T; Wybrańska I; Trznadel-Morawska I; Kiec-Wilk B; Borowiec M; Malecki MT
    Exp Clin Endocrinol Diabetes; 2015 Oct; 123(9):524-8. PubMed ID: 26240958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights from basic adjunctive examinations of GCK-MODY, HNF1A-MODY, and type 2 diabetes: A systemic review and meta-analysis.
    Liu J; Xiao X; Zhang Q; Yu M
    J Diabetes; 2023 Jun; 15(6):519-531. PubMed ID: 37226652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MODY probability calculator for GCK and HNF1A screening in a multiethnic background population.
    Tarantino RM; Abreu GM; Fonseca ACP; Kupfer R; Pereira MFC; Campos Júnior M; Zajdenverg L; Rodacki M
    Arch Endocrinol Metab; 2020 Feb; 64(1):17-23. PubMed ID: 31576961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel GCK and HNF1A/TCF1 mutations and polymorphisms in German families with maturity-onset diabetes of the young (MODY).
    Toaima D; Näke A; Wendenburg J; Praedicow K; Rohayem J; Engel K; Galler A; Gahr M; Lee-Kirsch MA
    Hum Mutat; 2005 May; 25(5):503-4. PubMed ID: 15841481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decision algorithm to identify patients with high probability of monogenic diabetes due to HNF1A mutations.
    Szopa M; Klupa T; Kapusta M; Matejko B; Ucieklak D; Glodzik W; Zapala B; Sani CM; Hohendorff J; Malecki MT; Skupien J
    Endocrine; 2019 Apr; 64(1):75-81. PubMed ID: 30778899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life assessment in patients with HNF1A-MODY and GCK-MODY.
    Szopa M; Matejko B; Ucieklak D; Uchman A; Hohendorff J; Mrozińska S; Głodzik W; Zapała B; Płatek T; Solecka I; Sani CM; Małecki MT
    Endocrine; 2019 May; 64(2):246-253. PubMed ID: 30421137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young.
    Ellard S; Thomas K; Edghill EL; Owens M; Ambye L; Cropper J; Little J; Strachan M; Stride A; Ersoy B; Eiberg H; Pedersen O; Shepherd MH; Hansen T; Harries LW; Hattersley AT
    Diabetologia; 2007 Nov; 50(11):2313-7. PubMed ID: 17828387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.
    Owen KR; Thanabalasingham G; James TJ; Karpe F; Farmer AJ; McCarthy MI; Gloyn AL
    Diabetes Care; 2010 Sep; 33(9):1919-24. PubMed ID: 20724646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes.
    McDonald TJ; Shields BM; Lawry J; Owen KR; Gloyn AL; Ellard S; Hattersley AT
    Diabetes Care; 2011 Aug; 34(8):1860-2. PubMed ID: 21700917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in HNF1A result in marked alterations of plasma glycan profile.
    Thanabalasingham G; Huffman JE; Kattla JJ; Novokmet M; Rudan I; Gloyn AL; Hayward C; Adamczyk B; Reynolds RM; Muzinic A; Hassanali N; Pucic M; Bennett AJ; Essafi A; Polasek O; Mughal SA; Redzic I; Primorac D; Zgaga L; Kolcic I; Hansen T; Gasperikova D; Tjora E; Strachan MW; Nielsen T; Stanik J; Klimes I; Pedersen OB; Njølstad PR; Wild SH; Gyllensten U; Gornik O; Wilson JF; Hastie ND; Campbell H; McCarthy MI; Rudd PM; Owen KR; Lauc G; Wright AF
    Diabetes; 2013 Apr; 62(4):1329-37. PubMed ID: 23274891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
    Pal A; Farmer AJ; Dudley C; Selwood MP; Barrow BA; Klyne R; Grew JP; McCarthy MI; Gloyn AL; Owen KR
    Diabetes Care; 2010 Feb; 33(2):252-7. PubMed ID: 19933992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of ACMG-AMP guidelines in HNF1A and GCK variants in a cohort of MODY families.
    Santana LS; Caetano LA; Costa-Riquetto AD; Quedas EPS; Nery M; Collett-Solberg P; Boguszewski MCS; Vendramini MF; Crisostomo LG; Floh FO; Zarabia ZI; Kohara SK; Guastapaglia L; Passone CGB; Sewaybricker LE; Jorge AAL; Teles MG
    Clin Genet; 2017 Oct; 92(4):388-396. PubMed ID: 28170077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.